中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

植物雌激素鹰嘴豆芽素A(BCA)对肝纤维化去势小鼠模型的改善作用及机制

谭超容 李小飘 冉俊艳 熊英 廖尚高 张金娟 何迅

引用本文:
Citation:

植物雌激素鹰嘴豆芽素A(BCA)对肝纤维化去势小鼠模型的改善作用及机制

DOI: 10.12449/JCH240114
基金项目: 

贵州省高层次创新型人才“百层次人才”项目 (Guizhou Kehe Platform Talents [2020] 6011)

伦理学声明:本课题实验方案于2021年7月9日获得贵州医科大学实验动物伦理委员会审批,批号:2100313,符合实验室动物管理与使用准则。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:谭超容参与课题的设计,负责课题实施,数据分析,撰写论文;李小飘、冉俊艳、熊英、廖尚高参与课题实施,数据收集,修改论文;张金娟、何迅负责课题设计,指导实验实施及文章撰写并定稿。
详细信息
    通信作者:

    张金娟, 826609585@qq.com (ORCID: 0000-00002-9078-531X)

    何迅, 2812878586@qq.com (ORCID: 0000-0002-1867-069X)

Role and mechanism of action of phytoestrogen biochanin A in improving liver fibrosis in ovariectomized mice

Research funding: 

Guizhou Provincial High-Level Innovative Talents “Hundred Level Talents” Project (Guizhou Kehe Platform Talents [2020] 6011)

More Information
  • 摘要:   目的  探究植物雌激素鹰嘴豆芽素A(BCA)对CCl4诱导的雌性双侧卵巢切除(去势)小鼠肝纤维化的影响及其机制。  方法  取50只去势雌性昆明小鼠,腹腔注射CCl4建立肝纤维化模型,将建模小鼠按体质量随机分成模型组、阳性对照组、BCA低、中、高剂量组各10只,同时选取10只同批雌性小鼠切除双侧卵巢旁少量脂肪组织作为假手术组。假手术组和模型组灌胃等体积的0.5%羧甲基纤维素钠溶液,阳性对照组用雌二醇2 mg/kg灌胃,BCA低、中、高剂量组分别按25、50、100 mg/kg BCA灌胃,1次/d,连续7周。给药结束后麻醉处死小鼠取材,测定肝指数和子宫指数,HE及Masson染色观察肝组织病理改变,生化法检测AST、ALT活性,ELISA法检测肝组织中IL-6、TNF-α水平,Western Blot法测定肝组织中Ⅰ型胶原蛋白(Collagen Ⅰ)、转化生长因子-β1(TGF-β1)、α-平滑肌肌动蛋白(α-SMA)、雌激素受体β(ERβ)、p-NF-κBp65/NF-κBp65蛋白的相对表达量。计量资料两组间比较采用成组t检验,多组间比较采用单因素方差分析;进一步两两比较采用LSD-t检验。非正态分布的计量资料多组间比较及进一步两两比较均采用Kruskal-Wallis H检验。  结果  与假手术组相比,模型组肝指数升高,子宫指数降低,血清AST和ALT活性、肝组织中IL-6、TNF-α水平及Collagen Ⅰ、TGF-β1、α-SMA、p-NF-κBp65/NF-κBp65蛋白表达均升高(P值均<0.05),肝组织ERβ表达变化不明显(P>0.05),模型组肝组织明显纤维化病变,出现肝细胞水肿、脂肪样变、坏死并伴有炎细胞浸润,胶原纤维增生沉积、交错分布。与模型组比较,BCA各剂量组肝指数降低,血清ALT和AST活性、肝组织IL-6、TNF-α水平及Collagen Ⅰ、TGF-β1、α-SMA、p-NF-κBp65/NF-κBp65的蛋白表达均降低(P值均<0.05),子宫指数无明显变化(P>0.05),肝组织ERβ蛋白表达升高(P<0.05),肝组织的纤维化病变有不同程度改善。  结论  BCA可有效改善CCl4诱导的雌性去势小鼠肝纤维化,其作用机制可能是通过上调ERβ抑制NF-κB信号通路,减轻炎症反应而实现的。

     

  • 图  1  BCA对CCl4诱导肝纤维化小鼠子宫、肝脏形态学及肝脏病理的影响

    Figure  1.  Effects of BCA on the morphological and pathological changes of uterus and liver in CCl4-induced liver fibrosis mice

    图  2  BCA对CCl4诱导肝纤维化小鼠蛋白表达的影响

    Figure  2.  Effects of BCA on protein expressions in CCl4-induced liver fibrosis mice

    表  1  BCA对CCl4诱导肝纤维化小鼠肝、子宫指数的影响

    Table  1.   Effects of BCA on liver and uterus weight ratios in CCl4-induced liver fibrosis mice

    组别 动物数(只) 肝指数 子宫指数
    假手术组 6 3.63%±0.35% 0.34%(0.27%~0.58%)
    模型组 6 5.29%±0.47%1) 0.09%(0.05%~0.34%)1)
    阳性对照组 6 4.97%±0.25% 0.49%(0.45%~0.65%)2)
    BCA低剂量组 6 4.51%±0.43%2) 0.11%(0.06%~0.33%)
    BCA中剂量组 6 4.54%±0.44%2) 0.08%(0.05%~0.32%)
    BCA高剂量组 6 4.64%±0.20%2) 0.10%(0.09%~0.11%)
    统计值 F=19.942 H=24.059
    P <0.000 1 <0.000 1
    注:与假手术组比较,1)P<0.05;与模型组比较,2)P<0.05。
    下载: 导出CSV

    表  2  BCA对CCl4诱导肝纤维化小鼠AST、ALT活性的影响

    Table  2.   Effects of BCA on serum activities of AST and ALT in CCl4-induced liver fibrosis mice

    组别 动物数(只) AST(U/L) ALT(U/L)
    假手术组 10 14.92±2.21 7.81±0.61
    模型组 10 43.65±17.711) 32.44±9.141)
    阳性对照组 10 20.56±5.322) 14.96±6.232)
    BCA低剂量组 10 21.17±3.872) 17.22±4.032)
    BCA中剂量组 10 20.72±6.482) 16.70±5.882)
    BCA高剂量组 10 19.66±4.682) 14.97±2.962)
    F 13.703 19.488
    P <0.000 1 <0.000 1
    注:与假手术组比较,1)P<0.05;与模型组比较,2)P<0.05。
    下载: 导出CSV

    表  3  BCA对CCl4诱导肝纤维化小鼠IL-6、TNF-α水平的影响

    Table  3.   Effects of BCA on serum contents of IL-6 and TNF-α in CCl4-induced liver fibrosis mice

    组别 动物数(只) IL-6(pg/mg) TNF-α(pg/mg)
    假手术组 10 107.43±21.23 37.01±12.16
    模型组 10 368.39±76.411) 94.49±26.511)
    阳性对照组 10 123.40±43.222) 43.05±11.702)
    BCA低剂量组 10 208.26±37.812) 70.77±9.782)
    BCA中剂量组 10 172.18±55.652) 53.43±14.382)
    BCA高剂量组 10 113.15±17.512) 40.63±17.442)
    F 31.623 12.645
    P <0.000 1 <0.000 1
    注:与假手术组比较,1)P<0.05;与模型组比较,2)P<0.05。
    下载: 导出CSV

    表  4  BCA对CCl4诱导肝纤维化小鼠肝组织中蛋白表达的影响

    Table  4.   Effects of BCA on protein expressions in CCl4-induced liver fibrosis mice

    组别 动物数(只) α-SMA TGF-β1 Collagen Ⅰ ERβ p-NF-κBp65/NF-κBp65
    假手术组 3 0.15±0.02 0.28±0.06 0.31±0.14 0.63±0.12 0.45±0.13
    模型组 3 0.39±0.051) 0.72±0.071) 0.60±0.021) 0.59±0.13 0.90±0.211)
    阳性对照组 3 0.26±0.102) 0.45±0.062) 0.42±0.032) 0.94±0.272) 0.41±0.182)
    BCA低剂量组 3 0.26±0.082) 0.56±0.092) 0.47±0.022) 0.83±0.15 0.64±0.12
    BCA中剂量组 3 0.19±0.062) 0.49±0.082) 0.43±0.022) 0.95±0.152) 0.45±0.092)
    BCA高剂量组 3 0.18±0.032) 0.47±0.062) 0.42±0.032) 0.98±0.152) 0.53±0.082)
    F 5.850 12.057 6.895 3.207 5.018
    P <0.006 <0.0001 <0.003 <0.046 <0.01
    注:与假手术组比较,1)P<0.05;与模型组比较,2)P<0.05。
    下载: 导出CSV
  • [1] LI MB, LI JY, FENG DP. Research advances in the reversal of liver fibrosis[J]. J Clin Hepatol, 2023, 39( 1): 193- 198. DOI: 10.3969/j.issn.1001-5256.2023.01.030.

    李满彪, 李金玉, 冯对平. 肝纤维化逆转的研究进展[J]. 临床肝胆病杂志, 2023, 39( 1): 193- 198. DOI: 10.3969/j.issn.1001-5256.2023.01.030.
    [2] AYDIN MM, AKÇALI KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29( 1): 14- 21. DOI: 10.5152/tjg.2018.17330.
    [3] XU LM, LIU P, Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine(2019 edition)[J]. J Integr Med, 2020, 18( 3): 203- 213. DOI: 10.1016/j.joim.2020.03.001.
    [4] YOON YJ, FRIEDMAN SL, LEE YA. Antifibrotic therapies: Where are we now?[J]. Semin Liver Dis, 2016, 36( 1): 87- 98. DOI: 10.1055/s-0036-1571295.
    [5] NASTA P. Immune activation, aging and gender and progression of liver disease[J]. Acta Biomed, 2011, 82( 2): 115- 123.
    [6] QIAO BK, MA XY, HAN LY, et al. Estrogen enhances liver repair by regulating hepatic cell regeneration[J]. J Southwest Univ Nat Sci Ed, 2020, 42( 8): 49- 58. DOI: 10.13718/j.cnki.xdzk.2020.08.007.

    乔冰珂, 马兴宇, 韩凌云, 等. 雌激素通过调控肝细胞更新促进CCl4诱导的肝损伤修复[J]. 西南大学学报(自然科学版), 2020, 42( 8): 49- 58. DOI: 10.13718/j.cnki.xdzk.2020.08.007.
    [7] CODES L, ASSELAH T, CAZALS-HATEM D, et al. Liver fibrosis in women with chronic hepatitis C: Evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy[J]. Gut, 2007, 56( 3): 390- 395. DOI: 10.1136/gut.2006.101931.
    [8] YANG WW, LU Y, XU YC, et al. Estrogen represses hepatocellular carcinoma(HCC) growth via inhibiting alternative activation of tumor-associated macrophages(TAMs)[J]. J Biol Chem, 2012, 287( 48): 40140- 40149. DOI: 10.1074/jbc.M112.348763.
    [9] XU JW, GONG J, FENG XL, et al. Effects of estrogen on the activation of hepatic stellate cells and collagen synthesis in liver fibrotic rats[J]. J Xi'an Jiaotong Univ Med Sci, 2003, 24( 6): 624- 626. DOI: 10.3969/j.issn.1671-8259.2003.06.032.

    许君望, 龚均, 冯新利, 等. 雌激素对肝纤维化大鼠肝星状细胞活化及胶原合成的影响[J]. 西安交通大学学报(医学版), 2003, 24( 6): 624- 626. DOI: 10.3969/j.issn.1671-8259.2003.06.032.
    [10] ROSSOUW JE, ANDERSON GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288( 3): 321- 33. DOI: 10.1001/jama.288.3.321
    [11] WANG H, ZHUANG W, XUE XO. Research progress and clinical application of phytoestrogen activity in traditional Chinese Medicine[J]. Jilin J Chin Med, 2018, 38( 3): 364- 368. DOI: 10.13463/j.cnki.jlzyy.2018.03.033.

    王浩, 庄威, 薛晓鸥. 中药植物雌激素活性研究及其临床应用研究进展[J]. 吉林中医药, 2018, 38( 3): 364- 368. DOI: 10.13463/j.cnki.jlzyy.2018.03.033.
    [12] WANG YX, WU CY, ZHOU JH, et al. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation[J]. BMC Pharmacol Toxicol, 2022, 23( 1): 77. DOI: 10.1186/s40360-022-00617-y.
    [13] DENG T, LIU J, ZHANG MM, et al. Inhibition effect of phytoestrogen calycosin on TGF-β1-induced hepatic stellate cell activation, proliferation, and migration via estrogen receptor B[J]. Can J Physiol Pharmacol, 2018, 96( 12): 1268- 1275. DOI: 10.1139/cjpp-2018-0474.
    [14] LI CW, WEI YL. Advances in studies on the characteristics and application of phytoestrogens[J]. Genom Appl Biol, 2020, 39( 3): 1264- 1269. DOI: 10.13417/j.gab.039.001264.

    李从文, 魏云林. 植物雌激素的特性及其应用研究进展[J]. 基因组学与应用生物学, 2020, 39( 3): 1264- 1269. DOI: 10.13417/j.gab.039.001264.
    [15] ZHAO Y, ZHENG HX, XU Y, et al. Research progress in phytoestrogens of traditional Chinese medicine[J]. China J Chin Mater Med, 2017, 42( 18): 3474- 3487. DOI: 10.19540/j.cnki.cjcmm.2017.0135.

    赵元, 郑红霞, 徐颖, 等. 中药植物雌激素的研究进展[J]. 中国中药杂志, 2017, 42( 18): 3474- 3487. DOI: 10.19540/j.cnki.cjcmm.2017.0135.
    [16] CHENG HL, WANG L, LUO Q, et al. Advances in studies on pharmacological effects of biochanin A[J]. J Liaoning Univ Tradit Chin Med, 2014, 16( 12): 92- 95. DOI: 10.13194/j.issn.1673-842x.2014.12.034.

    程海林, 王雷, 罗晴, 等. 鹰嘴豆芽素A基础药理作用研究进展[J]. 辽宁中医药大学学报, 2014, 16( 12): 92- 95. DOI: 10.13194/j.issn.1673-842x.2014.12.034.
    [17] ZHOU YM, NING HX, ZHANG XM, et al. Effects of biochanin A for osteoporosis in ovariecto-mized rats[J]. Chinese Pharmacological Bulletin, 2014, 30( 12): 1775- 1776. DOI: 10.3969/j.issn.1001-1978.2014.12.032.

    周延萌, 宁慧娴, 张小敏, 等. 鹰嘴豆芽素A对雌激素缺乏诱发大鼠骨质疏松症的作用[J]. 中国药理学通报, 2014, 30( 12): 1775- 1776. DOI: 10.3969/j.issn.1001-1978.2014.12.032.
    [18] KŘÍŽOVÁ L, DADÁKOVÁ K, KAŠPAROVSKÁ J, et al. Isoflavones[J]. Molecules, 2019, 24( 6): 1076. DOI: 10.3390/molecules24061076.
    [19] FAN Y, YAN LT, YAO Z, et al. Biochanin A regulates cholesterol metabolism further delays the progression of nonalcoholic fatty liver disease[J]. Diabetes Metab Syndr Obes, 2021, 14: 3161- 3172. DOI: 10.2147/DMSO.S315471.
    [20] TANG AC, WEI YF, LIU XH, et al. Protective effect and mechanism of tadehaginoside on hepatic fibrosis model mice induced by carbon tetrachloride[J]. China Pharm, 2020, 31( 2): 190- 195. DOI: 10.6039/j.issn.1001-0408.2020.02.12.

    唐爱存, 韦燕飞, 刘喜华, 等. 葫芦茶苷对四氯化碳致肝纤维化模型小鼠的保护作用及机制研究[J]. 中国药房, 2020, 31( 2): 190- 195. DOI: 10.6039/j.issn.1001-0408.2020.02.12.
    [21] SUN HT, CHEN GX, WEN B, et al. Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl4-induced liver fibrosis by suppressing NF-κB signaling and Wnt/β-catenin signaling[J]. J Pharmacol Sci, 2018, 136( 3): 133- 141. DOI: 10.1016/j.jphs.2018.01.003.
    [22] WANG ZR, TIAN FH, RAO MY, et al. Research progress of mice models for hepatic fibrosis[J]. China J Mod Med, 2021, 31( 12): 46- 50. DOI: 10.3969/j.issn.1005-8982.2021.12.009.

    王梓睿, 田飞鸿, 饶木艳, 等. 小鼠肝纤维化模型复制方法的研究进展[J]. 中国现代医学杂志, 2021, 31( 12): 46- 50. DOI: 10.3969/j.issn.1005-8982.2021.12.009.
    [23] HUANG FJ, ZHANG JJ, DONG L, et al. Preliminary study on improvement effect of Tiarella polyphylla ethanol extract on CCl4-induced hepatic fibrosis in mice and its mechanism[J]. China Pharm, 2021, 32( 14): 1685- 1691. DOI: 10.6039/j.issn.1001-0408.2021.14.04.

    黄甫静, 张金娟, 董莉, 等. 黄水枝醇提物对CCl4致小鼠肝纤维化的改善作用及其机制初探[J]. 中国药房, 2021, 32( 14): 1685- 1691. DOI: 10.6039/j.issn.1001-0408.2021.14.04.
    [24] JIANG Y, XIANG C, ZHONG F, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis[J]. Theranostics, 2021, 11( 1): 361- 378. DOI: 10.7150/thno.46360.
    [25] XIE JF. Effect and mechanism of CircRNA97 on reversing hepatic fibrosis through miRNA-146b-5p/HIPK1 axis[D]. Nanchang: Nanchang University, 2022. DOI: 10.27232/d.cnki.gnchu.2022.000617.

    谢俊锋. CircRNA97通过miRNA-146b-5p/HIPK1轴逆转肝纤维化的作用及机制研究[D]. 南昌: 南昌大学, 2022. DOI: 10.27232/d.cnki.gnchu.2022.000617
    [26] SUN ZC, ZHAN XL. Myrrhone inhibits the progression of hepatic fibrosis by regulating the abnormal activation of hepatic stellate cells[J]. J Biochem Mol Toxicol, 2022, 36( 11): e23177. DOI: 10.1002/jbt.23177.
    [27] LIN IY, CHIOU YS, WU LC, et al. CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-β, Wnt and STAT3 signaling pathways[J]. J Food Drug Anal, 2019, 27( 1): 184- 194. DOI: 10.1016/j.jfda.2018.09.008.
    [28] YANG JH, JU BW, XIANG XY, et al. Mechanism of inhibition of hepatic stellate cell activation by TGF-β1/Smad pathway regulated by Gentianella turkestanorum[J]. China J Tradit Chin Med Pharm, 2022, 37( 12): 7392- 7396.

    杨建华, 居博伟, 向雪滢, 等. 新疆假龙胆调控TGF-β1/Smad通路抑制肝星状细胞活化的作用机制[J]. 中华中医药杂志, 2022, 37( 12): 7392- 7396.
    [29] GE SF, YANG LX. Progress in the role of inflammation during the development of liver fibrosis[J]. Chin Hepatol, 2018, 23( 6): 546- 548. DOI: 10.14000/j.cnki.issn.1008-1704.2018.06.029.

    葛善飞, 杨丽霞. 炎症在肝纤维化发生中的作用研究进展[J]. 肝脏, 2018, 23( 6): 546- 548. DOI: 10.14000/j.cnki.issn.1008-1704.2018.06.029.
    [30] CUBERO FJ. Shutting off inflammation: A novel switch on hepatic stellate cells[J]. Hepatology, 2016, 63( 4): 1086- 1089. DOI: 10.1002/hep.28442.
    [31] ZHU H, PING J, XU LM. Role of the nuclear factor-kappa B signaling pathway on the progress of hepatic fibrosis and the anti-fibrotic mechanism of traditional Chinese medicine[J]. J Clin Hepatol, 2018, 34( 4): 858- 861. DOI: 10.3969/j.issn.1001-5256.2018.04.035.

    朱慧, 平键, 徐列明. NF-κB通路在肝纤维化进展和中药抗肝纤维化机制中的作用[J]. 临床肝胆病杂志, 2018, 34( 4): 858- 861. DOI: 10.3969/j.issn.1001-5256.2018.04.035.
    [32] LONG TT, LIU ZJ, SHANG JC, et al. Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-κB signaling pathways[J]. Int J Biol Macromol, 2018, 111: 813- 821. DOI: 10.1016/j.ijbiomac.2018.01.070.
    [33] TU KF, XU JY, YI ZZ. Relationship of the expression of estrogen receptor β and nuclear factor-kappa B of triple negative breast cancer[J]. J Mod Oncol, 2016, 24( 7): 1042- 1045. DOI: 10.3969/j.issn.1672-4992.2016.07.006.

    涂开峰, 徐久元, 易子桢. 三阴性乳腺癌中ERβ和NF-κB的表达及其相关性[J]. 现代肿瘤医学, 2016, 24( 7): 1042- 1045. DOI: 10.3969/j.issn.1672-4992.2016.07.006.
    [34] YAO Y. The role of ERβ in the occurrence and development of breast cancer through NF-κB/IL-8 signaling pathway[D]. Qingdao: Qingdao University, 2022. DOI: 10.27262/d.cnki.gqdau.2022.001348.

    姚瑶. ERβ通过NF-κB/IL-8信号通路在乳腺癌发生发展中作用探讨[D]. 青岛: 青岛大学, 2022. DOI: 10.27262/d.cnki.gqdau.2022.001348
  • 加载中
图(2) / 表(4)
计量
  • 文章访问数:  204
  • HTML全文浏览量:  75
  • PDF下载量:  32
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-03-09
  • 录用日期:  2023-03-29
  • 出版日期:  2024-01-23
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回